Drug

Ixazomib

Approved medicine

Class26S proteasome inhibitorResearchOngoing clinical research

Also known as Ninlaro, ((1R)-1-((2,5-DICHLOROBENZAMIDO)ACETAMIDO)-3-METHYLBUTYL)BORONIC ACID, BORONIC ACID, B-((1R)-1-((2-((2,5-DICHLOROBENZOYL)AMINO)ACETYL)AMINO)-3-METHYLBUTYL)-.

RxNorm1723735 ChEMBLCHEMBL2141296 ATCL01XG03UNII71050168A2

Active clinical trials

Protein targets

Latest activity

beta

Recent clinical, regulatory, research and industry developments relating to this drug.

Ixazomib Maintenance Following Initial Therapy in Patients With Immunoglobulin Light Chain (AL) Amyloidosis

Clinical trial2026-08-01Primary completion · ClinicalTrials.gov

An Open-label Phase I/II Trial of Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Systemic Light-Chain Amyloidosis

Clinical trial2026-07-10Results expected Q3 2027 · ClinicalTrials.gov

Exploratory Study of Ixazomib in Combination With Reduced Dose Lenalidomide Versus Ixazomib Alone for Maintenance Treatment of High Risk Multiple Myeloma

Clinical trial2026-06-30Primary completion · ClinicalTrials.gov

A Phase I/II Study of Ixazomib and Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma

Clinical trial2026-06-25Results posted · ClinicalTrials.gov

An Open-label Phase I/IIa Study to Evaluate the Safety and Efficacy of CCS1477 as Monotherapy and in Combination in Patients With Advanced Haematological Malignancies.

Clinical trial2026-06-24Results expected Q1 2027 · ClinicalTrials.gov

A Safety Study of Daratumumab, Ixazomib, and Dexamethasone in AL Amyloidosis

Clinical trial2026-06-17Completed · ClinicalTrials.gov

A Multi-center Open-label Phase 2 Study of Ixazomib, Iberdomide and Dexamethasone in Elderly Patients With Multiple Myeloma at First Relapse."

Clinical trial2026-06-15Results expected Q1 2030 · ClinicalTrials.gov

Multicenter Phase II Study of Ixazomib Maintenance in Patients With Newly Diagnosed Mantle Cell Lymphoma

Clinical trial2026-05-31Primary completion · ClinicalTrials.gov

A Phase 1b/2 Study of Selinexor (KPT-330) in Combination With Backbone Treatments for Relapsed/Refractory Multiple Myeloma and Newly Diagnosed Multiple Myeloma

Clinical trial2026-05-04Results expected Q2 2027 · ClinicalTrials.gov

A Phase 2 Study of Daratumumab, Bortezomib, and Dexamethasone (DVd), Followed by Daratumumab, Ixazomib, and Dexamethasone (DId) for Relapsed and/or Refractory Myeloma

Clinical trial2026-04-15Results expected Q4 2027 · ClinicalTrials.gov

A Phase 3, Multicenter, Randomized, Open-label Study to Compare the Efficacy and Safety of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM) (KarMMa-3)

Clinical trial2026-04-13Completed · ClinicalTrials.gov

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) in Combination With Lenalidomide and Dexamethasone (IRD) in Patients With Multiple Myeloma Previously Receiving a Bortezomib-Based Induction Regimen (US MM-6)

Clinical trial2026-03-30Terminated · ClinicalTrials.gov

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name

Ixazomib

Aliases & brands

Ninlaro((1R)-1-((2,5-DICHLOROBENZAMIDO)ACETAMIDO)-3-METHYLBUTYL)BORONIC ACIDBORONIC ACID, B-((1R)-1-((2-((2,5-DICHLOROBENZOYL)AMINO)ACETYL)AMINO)-3-METHYLBUTYL)-

RxNorm CUI

1723735

ChEMBL ID

CHEMBL2141296

ATC codes

L01XG03

UNII

71050168A2

Primary mechanism

26S proteasome inhibitor

Pharmacology & targets

38 targets

Known molecular targets and mechanisms supported by curated pharmacology databases.

26S proteasome non-ATPase regulatory subunit 1

PSMD1 · Q99460